多发性骨髓瘤细胞分子遗传学异常与预后分层、治疗

doi:10.16150/j.1671-2870.2017.05.002

摘要/Abstract

中图分类号:

R733.4

糜坚青, 金诗炜. 多发性骨髓瘤细胞分子遗传学异常与预后分层、治疗[J]. 诊断学理论与实践, 2017, 16(05): 460-463.

[1] Rajkumar SV.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management[J]. Am J Hematol,2016,91(7):719-734.
[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[3] Huang SY, Yao M, Tang JL, et al.Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years[J]. Cancer,2007,110(4):896-905.
[4] Kang SH, Kim TY, Kim HY, et al.Protective role of CYP1A1*2A in the development of multiple myeloma[J]. Acta Haematol,2008,119(1):60-64.
[5] Kim K, Lee JH, Kim JS, et al.Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study[J]. Am J Hematol,2014,89(7):751-756.
[6] Lee JH, Lee DS, Lee JJ, et al.Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party[J]. Int J Hematol,2010,92(1):52-57.
[7] Lu J, Lee JH, Huang SY, et al.Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial[J]. Br J Haematol,2017,176(5):743-749.
[8] Greenberg AJ, Rajkumar SV, Therneau TM, et al.Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma[J]. Leuk-emia,2014,28(2):398-403.
[9] Avet-Loiseau H.Role of genetics in prognostication in myeloma[J]. Best Pract Res Clin Haematol,2007,20(4):625-635.
[10] Weinhold N, Heuck CJ, Rosenthal A, et al.Clinical value of molecular subtyping multiple myeloma using gene expression profiling[J]. Leukemia,2016,30(2):423-430.
[11] National Comprehensive Cancer Network. Muliple Myeloma[R/OL]. 2016[2017-09-20]http://www.nccn.org/patients.
[12] Kaushansky主编,陈竺译. 威廉姆斯血液学[M]. 8版.人民卫生出版社,2011:11.
[13] An G, Xu Y, Shi L, et al.t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome[J]. Leuk Res,2013,37(10):1251-1257.
[14] Robillard N, Avet-Loiseau H, Garand R et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma[J]. Blood,2003,102(3):1070-1071.
[15] Caleb KS, Faith ED, Christoph H, et al.Molecular subtyping and risk stratification for the classification of myeloma[J]. J Auton Nerv Syst,2015,48(1):17-29.
[16] Avet-Loiseau H, Durie BG, Cavo M, et al.Combining fluo-rescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project[J]. Leukemia,2013,27(3):711-717.
[17] Mikhael JR, Dingli D, Roy V, et al.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013[J]. Mayo Clin Proc,2013,88(4):360-376.
[18] Sergentanis TN, Kastritis E, Terpos E, et al.Cytogenetics and survival of multiple myeloma: Isolated and combined effects[J]. Clin Lymphoma Myeloma Leuk,2016,16(6):335-340.
[19] Avet-Loiseau H, Leleu X, Roussel M, et al.Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)[J]. J Clin Oncol,2010,28(30):4630-4634.
[20] Sonneveld P, Avet-Loiseau H, Lonial S, et al.Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group[J]. Blood,2016,127(24):2955-2962.
[21] Yu W, Guo R, Qu X, et al.The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population[J]. Onco Targets Ther,2016,9:295-302.
[22] Grzasko N, Hus M, Pluta A, et al.Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients[J]. Hematol Oncol,2013,31(1):41-48.
[23] Shaughnessy JD Jr, Zhan F, Burington BE, et al.A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood,2007,109(6):2276-2284.
[24] Weinhold N, Heuck CJ, Rosenthal A, et al.Clinical value of molecular subtyping multiple myeloma using gene expression profiling[J]. Leukemia,2016,30(2):423-430.
[25] Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group[J]. J Clin Oncol,2015,33(26):2863-2869.
[26] Mikkilineni L, Kochenderfer JN. Chimeric Antigen Receptor T-cell Therapies for Multiple Myeloma[J]. Blood,2017,pii: blood-2017-06-793869.

多发性骨髓瘤细胞分子遗传学异常与预后分层、治疗

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.
[2]	寇明坤, 徐娜娜, 石静云, 吴涛. 达妥木单抗在多发性骨髓瘤一线治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(06): 588-591.
[3]	赵建治, 糜坚青. 多发性骨髓瘤相关生物标志物的研究进展[J]. 诊断学理论与实践, 2021, 20(05): 507-511.
[4]	范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海. MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400.
[5]	彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128.
[6]	陆弘逾, 曹亚峰, 顾俊, 王静, 陈梅, 宋陆茜. 神经电生理检查对多发性骨髓瘤患者硼替佐米治疗相关周围神经病的预测及诊断意义[J]. 诊断学理论与实践, 2019, 18(06): 640-644.
[7]	汪萍, 沈立松, 张冬青. 多发性骨髓瘤及相关疾病的实验室诊断认识[J]. 诊断学理论与实践, 2017, 16(05): 477-483.
[8]	李晓帆, 王少元. 多发性骨髓瘤微小残留病检测及其临床应用[J]. 诊断学理论与实践, 2017, 16(05): 472-476.
[9]	曹亚峰, 王静, 顾俊, 陆弘逾, 许杰, 刘元坊, 王焰, 王瑾, 陈钰, 陈玉宝, 李佳明, 郝杰, 糜坚青, 陈梅. 以硼替佐米为基础的联合方案治疗114例初诊多发性骨髓瘤患者的周围神经病变分析[J]. 诊断学理论与实践, 2017, 16(05): 492-497.
[10]	侯健, 刘进. 2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读[J]. 诊断学理论与实践, 2017, 16(05): 455-459.
[11]	王敏敏, 颜敏超, 郭晓珺. 硼替佐米和沙利度胺治疗多发性骨髓瘤致相关周围神经病变机制[J]. 诊断学理论与实践, 2016, 15(06): 629-631.
[12]	刘占云, 王艳煜, 俞娇, 陈秋生, 李军民, 赵维莅,. 可溶性CD40在部分B细胞淋巴血液肿瘤患者中的表达及临床意义[J]. 诊断学理论与实践, 2012, 11(06): 620-623.
[13]	张曦, 常春康, 吴凌云, 周立宇, 苏基滢, 李晓,. 多发性骨髓瘤患者白蛋白校正后高血钙发生率的研究[J]. 诊断学理论与实践, 2010, 9(03): 233-235.
[14]	黄琴, 张晓燕, 王晓敏,. 多发性骨髓瘤患者血清IL-6的测定及其临床意义[J]. 诊断学理论与实践, 2010, 9(03): 264-265.
[15]	李雪华, 张曦, 常春康, 李晓, 浦权,. 205例多发性骨髓瘤患者骨髓涂片与活检切片内浆细胞浸润的比较研究[J]. 诊断学理论与实践, 2010, 9(01): 63-65.